Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02103270 · ClinicalTrials.gov registry record · Phase 2
The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT02103270: Completed Phase 2 study, sponsored by Stanford University.
NCT02103270 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02103270, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
Determine whether peanut oral immunotherapy (OIT) induces clinical tolerance as assessed after the initial 3 month avoidance period Secondary Objectives: * Identify the basic immune mechanisms which can explain the differences in the effects of OIT in desensitized vs. tolerant individuals. * Determine whether immune monitoring measurements reflecting underlying mechanisms during OIT can be used to predict responses to OIT in individual subjects and, ultimately, to improve the safety and efficacy outcomes in peanut OIT protocols.
Primary Outcome
Number of Participants with No Clinical Reactivity to Peanuts
Interventions
- DRUG Oat Flour
- DRUG Peanut Protein 4,000mg
- DRUG Peanut Protein 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-09-01 |
| Phase | Phase 2 |
What the finished NCT02103270 record still lists
NCT02103270 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 3 interventions - of which Oat Flour is the first listed.
NCT02103270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02103270 about?
NCT02103270 is a clinical study titled "The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery". Determine whether peanut oral immunotherapy (OIT) induces clinical tolerance as assessed after the initial 3 month avoidance period Secondary Objectives: * Identify the basic immune mechanisms which can explain the differences in the effects of OIT in desensitized vs. tolerant individuals. * Deter...
What is the current status of trial NCT02103270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2014-04. Estimated completion is 2018-09-01.
What interventions are being tested in trial NCT02103270?
The interventions under investigation include: Oat Flour (DRUG), Peanut Protein 4,000mg (DRUG), Peanut Protein 300 mg (DRUG).
Who is sponsoring clinical trial NCT02103270?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02103270's enrollment target sits among peer trials
120 569th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia